Thyroseq V3 Molecular Profiling for Tailoring the Surgical Management of Hürthle Cell Neoplasms

Pearlstein, Sarah; Lahouti, Arash H.; Opher, Elana; Nikiforov, Yuri E.; Kuriloff, Daniel B.

doi:10.1155/2018/9329035

Cited by 8 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported a case of Hürthle cell neoplasm analyzed with ThyroSeq v3 test, showing CNAs involving multiple chromosomes with the pattern of genome haploidization more frequently found in Hürthle cell malignancy rather than Hürthle cell metaplasia or an adenoma. The histological report confirmed a 7-cm Hürthle cell carcinoma with five foci of angioinvasion found along with foci of capsular invasion, without extrathyroidal extension ( 37 ). The possibility to evaluate CNAs is important for the prediction of Hürthle cell carcinomas, which are known to have a characteristic pattern of CNAs with almost complete genome haploidization ( 38 ).…”

Section: Molecular Characterization Of Thyroid Lesionsmentioning

confidence: 61%

Molecular Characterization of Thyroid Follicular Lesions in the Era of “Next-Generation” Techniques

et al. 2022

View full text Add to dashboard Cite

It is unequivocally recognized that thyroid nodules are frequently detected in the adult population and mostly characterized by benign lesions (up to 70% of them), with only 5%–15% malignant lesions. The evaluation of thyroid lesions with fine-needle aspiration cytology (FNAC) represents one of the first and most useful diagnostic tools in the definition of their nature. Despite the fact that the majority of thyroid lesions are correctly diagnosed as either benign (70%–75%) or malignant (5%–10%) entities, the remaining nodules (20%–25%) represent the “gray zone” of follicular lesions, which belong to indeterminate categories, according to the different classification systems. This indeterminate group of lesions includes both benign and malignant entities, which cannot be easily discriminate with morphology alone. In these last decades, the increasing role of molecular testings, feasibly performed on cytological material combined with the discoveries of specific genetic alterations in the field of thyroid pathology, has opened the pace to their more accurate and specific contribution on cytology. In fact, in 2015, in the revised management guidelines for patients with thyroid nodules and well-differentiated thyroid cancers (WDTCs), the American Thyroid Association (ATA) confirmed the performance of molecular testing in thyroid indeterminate cytology, and the same performance was addressed in recent update of the management of thyroid nodules in the second edition of the Bethesda system for reporting thyroid cytopathology (TBSRTC). In the current review, we discuss the role of molecular tests for the different thyroid diagnostic categories of the Bethesda system for reporting thyroid cytopathology, mostly focusing our attention on the follicular and indeterminate lesions.

show abstract

Section: Molecular Characterization Of Thyroid Lesionsmentioning

confidence: 61%

Molecular Characterization of Thyroid Follicular Lesions in the Era of “Next-Generation” Techniques

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Subsequent investigations into the use of molecular testing, and in particular the commercial tests, in guiding extent of surgery have been limited to case reports [c.f. ( 47 )].…”

Section: Impact On Surgical Practicementioning

confidence: 99%

Thyroid Nodule Molecular Testing: Is It Ready for Prime Time?

Khan

Zeiger

2020

Front. Endocrinol.

View full text Add to dashboard Cite

Cytologically indeterminate thyroid nodules remain a diagnostic and clinical challenge, and molecular testing has been advocated and advanced as a diagnostic modality to help guide treatment. While studies have expounded on the improved diagnostic certainty with these tests, data demonstrating meaningful clinical impact and supporting their routine use is still limited at best. In this review, we discuss the limitations regarding diagnostic accuracy, impact on surgical decision-making and outcomes, and cost-effectiveness of molecular testing. By highlighting the limitations of these tests, we aim to promote more thoughtful utilization of these tools in the management of thyroid nodules going forward.

show abstract

“…HTC is characterized by a capsular and vascular invasion, while benign Hürthle cell adenoma lacks invasive features [4]. Thus, a detailed histopathological characterization is required in order to distinguish between benign Hürthle cell adenoma and HTC [12]. However, the inability to predict from FNAB specimens which Hürthle cell neoplasm is malignant has led to surgical over-treatment [4,13].…”

Section: Introductionmentioning

confidence: 99%

The Molecular Landscape of Hürthle Cell Thyroid Cancer Is Associated with Altered Mitochondrial Function—A Comprehensive Review

Kumari

Adewale

Kłubo-Gwieździńska

2020

Cells

View full text Add to dashboard Cite

Hürthle cell thyroid carcinoma (HTC) accounts for 3–5% of all thyroid malignancies. Widely invasive HTC is characterized by poor prognosis and limited responsiveness to standard therapy with radioiodine. The molecular landscape of HTC is significantly different from the genetic signature seen in other forms of thyroid cancer. We performed a comprehensive literature review on the association between the molecular features of HTC and cancer metabolism. We searched the Pubmed, Embase, and Medline databases for clinical and translational studies published between 1980 and 2020 in English, coupling “HTC” with the following keywords: “genomic analysis”, “mutations”, “exome sequencing”, “molecular”, “mitochondria”, “metabolism”, “oxidative phosphorylation”, “glycolysis”, “oxidative stress”, “reactive oxygen species”, and “oncogenes”. HTC is characterized by frequent complex I mitochondrial DNA mutations as early clonal events. This genetic signature is associated with the abundance of malfunctioning mitochondria in cancer cells. HTC relies predominantly on aerobic glycolysis as a source of energy production, as oxidative phosphorylation-related genes are downregulated. The enhanced glucose utilization by HTC is used for diagnostic purposes in the clinical setting for the detection of metastases by fluorodeoxyglucose positron emission tomography (FGD-PET/CT) imaging. A comprehensive metabolomic profiling of HTC in association with its molecular landscape might be necessary for the implementation of tumor-specific therapeutic approaches.

show abstract

Thyroseq V3 Molecular Profiling for Tailoring the Surgical Management of Hürthle Cell Neoplasms

Cited by 8 publications

References 6 publications

Molecular Characterization of Thyroid Follicular Lesions in the Era of “Next-Generation” Techniques

Molecular Characterization of Thyroid Follicular Lesions in the Era of “Next-Generation” Techniques

Thyroid Nodule Molecular Testing: Is It Ready for Prime Time?

The Molecular Landscape of Hürthle Cell Thyroid Cancer Is Associated with Altered Mitochondrial Function—A Comprehensive Review

Contact Info

Product

Resources

About